GlassScriptPhysician profile
Patricia E Pacetti
NPI 1982845590
$4,330.47
in general payments reported to CMS, 2019-2025
26 companies · $1,257 in 2025
The $1,257 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $652 · 2023: $782 · 2024: $1,506 · 2025: $1,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,544.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $471.61 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $453.85 | 2022-2023 | Xarelto |
| Amgen INC. | $443.58 | 2023-2025 | Repatha, Evenity |
| Madrigal Pharmaceuticals | $271.64 | 2024-2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $251.13 | 2024-2025 | Airsupra |
| Mylan Specialty L.P. | $224.30 | 2023 | Yupelri |
| Esperion Therapeutics, INC. | $219.08 | 2021-2022 | |
| Cequr Corporation | $150.00 | 2024 | Cequr Simplicity |
| Alnylam Pharmaceuticals INC. | $145.73 | 2025 | Amvuttra |
| Abbott Laboratories | $137.56 | 2022-2023 | Aveir, Jot Dx, Ensite |
| Abiomed | $130.35 | 2025 | |
| Agios Pharmaceuticals, INC. | $126.30 | 2025 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $124.25 | 2025 | Strensiq |
| Impulse Dynamics (USA) INC. | $122.15 | 2023 | Optimizer |
| Eisai INC. | $122.07 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $119.17 | 2024 | |
| Neurocrine Biosciences, INC. | $108.44 | 2022 | |
| Abbvie INC. | $106.81 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $104.00 | 2023 | Jynarque |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.89 | 2024 | Xifaxan |
| Alkermes, INC. | $98.83 | 2024 | Vivitrol |
| Glaxosmithkline, LLC. | $89.45 | 2024 | |
| Inspire Medical Systems, INC. | $75.62 | 2024 | Inspire |
| Agile Therapeutics, INC. | $73.15 | 2022 | |
| Xeris Pharmaceuticals, INC. | $43.53 | 2024 | Recorlev |
| Medtronic, INC. | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Pacetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.